Financial Performance - The group recorded a revenue increase of 29.2%, rising from approximately SGD 10.4 million in the fiscal year 2018 to about SGD 13.5 million in the fiscal year 2019[9]. - The profit for the fiscal year 2019 was approximately SGD 0.6 million, compared to a loss of SGD 0.7 million in the fiscal year 2018[9]. - The total revenue for the year was approximately SGD 13,462,000, an increase of about SGD 3,041,000 or 29.2% compared to SGD 10,421,000 in the 2018 fiscal year[15]. - Revenue from consultation services, medical examination services, and treatment services were approximately SGD 1.355 million, SGD 4.040 million, and SGD 8.067 million, respectively, accounting for 10.1%, 30.0%, and 59.9% of total revenue[14]. - Revenue from diagnostic services increased from approximately SGD 1,057,000 in 2018 to SGD 1,356,000 in the current year, a rise of about SGD 299,000[17]. - Revenue from medical examination services rose from approximately SGD 3,017,000 in 2018 to SGD 4,040,000, an increase of about SGD 1,023,000, maintaining a contribution percentage of around 30.0%[17]. - Revenue from treatment services grew from approximately SGD 6,263,000 in 2018 to SGD 8,067,000, an increase of about SGD 1,804,000, with a stable contribution percentage of approximately 59.9%[17]. - The company recorded a profit of approximately SGD 638,000 for the year, an increase of about SGD 1.4 million compared to a loss of approximately SGD 731,000 in the 2018 fiscal year[31]. - The income tax expense for the year was approximately SGD 462,000, compared to SGD 87,000 in the 2018 fiscal year[29]. Operational Developments - The company plans to establish three new consultation centers in the fiscal year 2020, currently under renovation[10]. - The company operates a network of seven DTAP consultation centers and one SA consultation center as of the report date[10]. - The group expects a challenging and competitive business environment moving forward[10]. - The company aims to expand market share and enhance the Dr. Tan & Partners brand reputation in the healthcare services industry in Singapore[14]. - The group will continue to manage expenses, particularly labor costs, by upgrading and utilizing technology[10]. Employee and Labor Costs - Employee benefits expenses increased by SGD 893,000 or 24.4% to SGD 4,552,000 due to an increase in the number of employees[22]. - The total number of employees increased from 33 in 2018 to 51 in 2019[23]. - Employee costs for the year were approximately SGD 4.6 million, up from SGD 3.7 million in the fiscal year 2018, with a total of 51 employees as of December 31, 2019[43]. Financial Position - Total equity of the group as of December 31, 2019, was approximately SGD 13.2 million, an increase from SGD 12.6 million in the fiscal year 2018[34]. - Cash and bank balances as of December 31, 2019, were approximately SGD 5.9 million, down from SGD 12.4 million in the fiscal year 2018[34]. - Net cash generated from operating activities was approximately SGD 2.7 million, compared to a net cash outflow of SGD 0.3 million in the fiscal year 2018[34]. - The group's capital debt ratio as of December 31, 2019, was 18.6%, a significant increase from 0.0% in the fiscal year 2018[34]. Corporate Governance - The company is committed to maintaining high standards of accountability and ethical conduct in its operations[69]. - The board includes independent non-executive directors with extensive experience in finance and auditing, enhancing corporate governance[69][70]. - The company has adopted and complied with all applicable corporate governance code provisions as per the GEM listing rules for the year ending December 31, 2019[150]. - The company has established a strong internal control and risk management framework to ensure effective accountability[149]. - The company has confirmed that all directors have complied with the trading code as per GEM listing rules during the year[151]. Shareholder Information - The company did not declare a final dividend for the year[33]. - The group did not declare any dividends for the current year, consistent with the previous year[87]. - As of December 31, 2019, the group had no distributable reserves, unchanged from 2018[97]. - The next annual general meeting is scheduled for June 26, 2020, with a suspension of share transfer registration from June 22 to June 26, 2020[88]. Strategic Initiatives - The company aims to expand its market presence and enhance its operational efficiency through strategic initiatives[81]. - The company spent SGD 2.6 million to strategically expand and consolidate the DTAP treatment center network, with SGD 497,000 already utilized by the first half of 2021[54]. - A total of SGD 4.3 million was allocated for the continuous recruitment and retention of doctors and staff, with SGD 1.091 million utilized by the second half of 2021[54]. - The company invested SGD 600,000 to enhance and improve its IT infrastructure, with SGD 176,000 spent by the second half of 2020[54]. Compliance and Legal Matters - The company has confirmed compliance with non-competition agreements by all controlled persons during the year[118]. - The company has not disclosed any significant events that require disclosure after December 31, 2019, up to the date of the report[142]. - The company has complied with all relevant laws and regulations affecting its business operations during the year, with no significant violations reported[138]. Audit and Financial Reporting - The audit committee has reviewed the audited consolidated financial statements for the year and confirmed they were prepared in accordance with applicable accounting standards and GEM listing rules[146]. - Baker Tilly TFW LLP has been appointed as the independent auditor for the company, succeeding PwC, and will be proposed for reappointment at the 2020 annual general meeting[147]. - The external auditor's fees for the year ending December 31, 2019, amounted to SGD 120,000 for audit services, with no fees for non-audit services[191].

REPUBLIC HEALTHCARE LIMITED （於開曼群島註冊成立的有限公司） 股份代號: 8357 第三季度 報告 2019 (Incorporated in the Cayman Islands with limited liability) Stock Code: 8357 REPUBLIC HEALTHCARE LIMITED Third Quarterly Report 2019 香港聯合交易所有限公司GEM（分別稱為「聯交所」及「GEM」）的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在主板上市的公司帶 有較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考 慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於聯交所主板買賣之證券 承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本報告全部或任何部分而產生或因倚賴該等內容而引致之任何 損失承擔任何責任。 本報告乃 ...

Financial Performance - The group recorded revenue of approximately SGD 6.3 million for the six months ended June 30, 2019, an increase of about 13.1% compared to SGD 5.5 million for the same period in 2018[9] - Gross profit for the period remained stable at SGD 3.9 million, consistent with the previous year[10] - The group achieved a net profit after tax of approximately SGD 0.6 million, a significant turnaround from a net loss of SGD 1.5 million in the same period last year, primarily due to a one-time non-recurring listing expense of approximately SGD 2.5 million incurred in the prior year[10] - Total revenue for the six months ended June 30, 2019, was SGD 6,250,853, an increase of 14.5% from SGD 5,457,229 in the same period of 2018[42] - Treatment services revenue reached SGD 3,613,779, up 9.8% from SGD 3,292,098 in 2018[42] - Medical examination services revenue increased by 25.8% to SGD 2,020,776 from SGD 1,606,447 in 2018[42] - The company reported a profit attributable to owners of SGD 556,884 for the six months ended June 30, 2019, compared to a loss of SGD 1,515,956 in the same period of 2018[46] - Basic earnings per share for the period was SGD 0.12, compared to a loss per share in the previous year[46] Assets and Liabilities - Total assets increased to SGD 15.8 million as of June 30, 2019, compared to SGD 14.2 million as of December 31, 2018[15] - Cash and cash equivalents rose to SGD 13.5 million from SGD 12.4 million at the end of 2018[15] - Trade receivables increased significantly to SGD 127,773 from SGD 55,787 in the previous year[15] - Total equity increased to SGD 13.1 million as of June 30, 2019, compared to SGD 12.6 million at the end of 2018[16] - The group reported total liabilities of SGD 2.7 million, up from SGD 1.5 million at the end of 2018[16] - Trade payables rose significantly to SGD 1,002,955 as of June 30, 2019, compared to SGD 388,119 at the end of 2018[57] - The company reported accrued operating expenses of SGD 658,295 as of June 30, 2019, up from SGD 556,914 at the end of 2018[58] Cash Flow and Capital Management - The company reported a net cash inflow from operating activities of SGD 1,436,291 for the six months ended June 30, 2019, compared to a cash outflow of SGD 1,021,717 in the same period of 2018[21] - Cash and cash equivalents as of June 30, 2019, totaled SGD 13,526,026, an increase from SGD 12,370,343 at the end of 2018[54] - The company has no bank borrowings as of June 30, 2019, consistent with the previous year[81] - The company’s retained earnings as of June 30, 2019, stood at SGD 1,104,685, reflecting an increase from SGD 547,801 at the beginning of the year[18] - The company’s capital management objective is to ensure the group can continue as a going concern while providing returns to shareholders[36] Corporate Governance and Compliance - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited condensed consolidated financial statements and found them compliant with applicable accounting standards[121] - The company is committed to maintaining high standards of corporate governance and has adopted all applicable code provisions of the GEM Listing Rules[115] - The company has established an audit committee to oversee financial reporting and risk management processes[121] - No directors or controlling shareholders have interests in any competing businesses during the reporting period[114] - The company has complied with the GEM Listing Rules regarding securities trading by directors[116] Future Plans and Investments - The company is focused on maintaining operational efficiency and exploring new market opportunities to drive future growth[10] - The net proceeds from the IPO of approximately SGD 9.1 million will be used for future expansion and business growth in Singapore[69] - The company operates seven DTAP centers and two SA centers, with plans to open another center in Bukit Timah[68] - The company has plans to open a new DTAP treatment center in the northeastern part of Singapore, postponed to the first half of 2021 due to space availability[102] - The company spent SGD 241,000 on renovations for three new DTAP treatment centers during the period[95] - The company allocated SGD 63,000 for upgrading its information technology infrastructure and systems as of June 30, 2019[99] Risks and Contingencies - The company has not faced any major foreign exchange risks as all transactions are conducted in Singapore dollars[89] - The company has not utilized any hedging contracts for speculative activities during the period[90] - There are no significant contingent liabilities reported as of June 30, 2019[87] - There are no significant events affecting the company reported after June 30, 2019[93]

Financial Performance - The group recorded revenue of SGD 2.8 million for the three months ended March 31, 2019, representing an increase of approximately 10.5% compared to SGD 2.6 million for the same period in 2018[6]. - The net profit for the period was approximately SGD 0.3 million, unchanged from the previous year, primarily due to increased employee and operating expenses offsetting revenue growth[6]. - The group reported a gross profit of SGD 323,000 for the period, slightly up from SGD 307,000 in the previous year[9]. - Total comprehensive income attributable to owners of the company for the period was SGD 268,000, compared to SGD 255,000 in the previous year[9]. - Revenue increased by approximately SGD 0.3 million or 10.5% year-on-year, reaching about SGD 2.8 million for the quarter ended March 31, 2019[31]. - Net profit attributable to owners was approximately SGD 0.3 million, consistent with the same period last year[35]. - Earnings per share decreased to 0.05 Singapore cents from 0.06 Singapore cents year-on-year, with issued shares increasing from 390 million to 520 million[25]. Expenses and Costs - Employee benefits expenses increased to SGD 916,000 from SGD 713,000 in the previous year, reflecting higher operational costs[9]. - Employee benefits expenses rose by approximately SGD 0.2 million or 28.5% to about SGD 0.9 million, primarily due to hiring for new treatment centers[33]. - Other operating expenses increased by approximately SGD 0.3 million, attributed to higher marketing and legal costs post-IPO[34]. Dividends and Equity - The company did not declare any dividends for the period, consistent with the previous year[7]. - The company has no bank borrowings and maintains a strong liquidity position with no significant contingent liabilities[39][43]. - The company’s total equity as of March 31, 2019, was SGD 12.84 million, an increase from SGD 12.57 million at the beginning of the year[11]. - No dividends were declared for the period, consistent with the previous year[36]. Business Operations and Expansion - Medical services revenue included SGD 1.7 million from treatment services, SGD 0.9 million from medical examination services, and SGD 0.3 million from consultation services[19]. - The company opened two new treatment centers during the period, expanding its network under the "Dr. Tan & Partners" brand[27]. - The group continues to focus on expanding its healthcare services in Singapore, leveraging its existing facilities and expertise[14]. Compliance and Governance - The financial statements were prepared in accordance with International Financial Reporting Standards and GEM listing rules, ensuring compliance and transparency[15]. - The company has complied with all applicable corporate governance codes as per GEM Listing Rules[60]. - The audit committee, consisting of three independent non-executive directors, has reviewed the financial statements and found them compliant with applicable accounting standards[65]. - There were no interests held by directors or controlling shareholders in any competing businesses during the reporting period[58]. Shareholding Structure - As of March 31, 2019, the company had a total of 520,000,000 shares issued[52]. - Dr. Chen holds 390,000,000 shares, representing 75% of the company's issued shares[56]. - Cher Sen Holdings Limited, controlled by Dr. Chen, owns 390,000,000 shares, also accounting for 75% of the issued shares[56]. - Dr. Chen is the beneficial owner of 50,000 shares in Cher Sen, representing 100% of that entity[53]. - No other entities, apart from those disclosed, held any significant interests in the company's shares as of March 31, 2019[57]. Other Information - The company has not disclosed any new product developments or market expansions in the provided documents[64]. - No securities were repurchased or sold by the company during the reporting period[63]. - The management emphasizes ongoing investment in technology to maintain competitive advantages, particularly in the medical aesthetics sector[28].

Financial Performance - The group's revenue for the fiscal year ended December 31, 2018, was approximately SGD 10.4 million, an increase of about 4.7% compared to SGD 10.0 million for the fiscal year ended December 31, 2017[10]. - The group recorded a loss of approximately SGD 0.7 million for the fiscal year, compared to a profit of SGD 2 million in the previous fiscal year, primarily due to non-recurring listing expenses of about SGD 2.1 million[10]. - Adjusted profit for the fiscal year was approximately SGD 1.4 million, down from SGD 2.7 million in the previous fiscal year, mainly due to costs incurred post-listing[10]. - The group's total revenue for the year was approximately SGD 10,421,000, an increase of about SGD 465,000 or 4.7% compared to SGD 9,957,000 in FY2017[16]. - Revenue from medical examination services increased by SGD 100,000 to SGD 3,017,000, maintaining a stable contribution percentage of 29%[19]. - Revenue from treatment services rose by SGD 800,000 to SGD 6,263,000, with its contribution percentage increasing from 54.8% in FY2017 to 60.1% in FY2018[19]. - The group recorded a loss of approximately SGD 731,000 for the year, a decline of about SGD 2.7 million compared to a profit of SGD 2 million in FY2017[34]. - Listing expenses totaled approximately SGD 3.9 million for the year, significantly up from SGD 743,000 in FY2017[35]. - The group did not declare a final dividend for the year, following a total dividend distribution of approximately SGD 2.2 million in FY2017[38]. Revenue Breakdown - Revenue from consultation services, treatment services, and medical examination services were approximately SGD 1.1 million, SGD 6.3 million, and SGD 3.0 million, respectively, accounting for 10.1%, 60.0%, and 29.0% of total revenue[15]. Expenses and Costs - Employee benefits expenses increased by SGD 861,000 or 30.8% to SGD 3,659,000 due to an increase in the number of employees[26]. - Other operating expenses grew by approximately SGD 1,788,000 or 87.8% to about SGD 3,825,000, largely due to increased listing expenses[30]. - Employee costs for the year amounted to approximately SGD 3.7 million, up from SGD 2.8 million in the fiscal year 2017[47]. Assets and Equity - Total equity as of December 31, 2018, was approximately SGD 12.6 million, up from SGD 1.7 million in the fiscal year 2017[39]. - Cash and bank balances as of December 31, 2018, were approximately SGD 12.4 million, compared to SGD 2.0 million in the fiscal year 2017[39]. - Net current assets as of December 31, 2018, were approximately SGD 11.7 million, an increase from SGD 876,000 in the fiscal year 2017[39]. - The capital debt ratio as of December 31, 2018, was 0.0%, consistent with the fiscal year 2017[39]. Future Plans and Expansion - The net proceeds from the listing amounted to approximately SGD 9.1 million, which will be used for future expansion and business growth in Singapore[11]. - The company aims to expand its market share and enhance the DTAP brand reputation in the competitive healthcare services industry in Singapore[15]. - The company has delayed the opening of a new DTAP clinic in western Singapore to mid-2019 due to the availability of suitable rental space, with approximately SGD 1.1 million from the IPO proceeds remaining unutilized[61]. - The company has begun the design work for IT infrastructure and systems for the clinics, having selected suppliers and paid a deposit of SGD 57,000[63]. - The company has identified Holland Village as a suitable location for the new DTAP clinic, with renovations planned[63]. Governance and Leadership - The company has a strong governance structure with independent non-executive directors overseeing key committees such as audit, nomination, and remuneration[76][78]. - The company has established a strong foundation for future growth with experienced leadership in both medical and financial sectors[81][82]. - The board includes members with diverse backgrounds in finance, healthcare, and technology, contributing to a well-rounded strategic direction[76][82]. - The independent directors provide independent judgment on strategies, policies, and accountability standards, ensuring robust governance[76][78]. - The company is committed to maintaining high standards of corporate governance and regularly reviews its practices[146]. Committees and Meetings - The company has established three committees: Audit Committee, Nomination Committee, and Remuneration Committee, to oversee specific aspects of its affairs[186]. - The Audit Committee monitors the integrity of the company's financial statements and reviews significant judgments related to financial reporting[190]. - The Nomination Committee is tasked with reviewing the company's corporate governance policies and practices, making recommendations to the board[195]. - The Remuneration Committee reviewed matters related to the remuneration of directors and senior management during a meeting on March 27, 2019, providing recommendations to the board[199]. Shareholder Information - As of December 31, 2018, a director held 390 million shares, representing 75% of the company's issued shares, through a controlled corporation[135]. - The company maintains a sufficient public float, with at least 25% of its issued shares held by the public[148]. - The company has not repurchased any of its listed securities during the period[108].